BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.14 +1.67%
EPS Growth %: -13.3%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: -13.3%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), versus ($0.34) reported last year. Revenue for the quarter came in at $47.2 million, versus $4 million reported last year.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- AXT appoints Tracy Liu to its board of directors
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
